Our lead candidate, TRB-N0224, is envisioned as the first FDA-approved, once-daily, edible prescription medication for the prevention and control of canine periodontal disease.

TRB-N0224 is a chemically modified curcumin selected from a proprietary library of polyenolic zinc-binding agents developed at Stony Brook University by Drs. Lorne Golub and Francis Johnson.  Dr. Golub is also the lead inventor of zinc-binding, sub-antimicrobial dose tetracycline (Periostat® and Oracea®), now marketed by Galderma, from which these novel curcumin analogues were designed.

TRB-N0224 acts to resolve inflammation through pleiotropic modulation of pathologically-elevated matrix metalloproteinases (MMPs) and pro-inflammatory mediators.  TRB-N0224 has demonstrated efficacy in treating periodontal disease in several laboratory rodent models, with no observed toxicity at over 15 times the therapeutic dose.  TRB-N0224 is synthesized in a scalable, two-reaction process from inexpensive and readily-available raw materials.